Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia.

摘要

ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-ABL(T315I) mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer Cell, that switch-control switching from the inactive to active conformation.